T11	Exp 105 108	its
T12	Exp 211 215	that
T13	Exp 176 201	The therapeutic potential
T14	Exp 222 235	the induction
T15	Exp 549 551	we
T16	Exp 385 452	its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid
T17	Exp 277 281	When
T18	Exp 561 565	that
T19	Exp 894 896	we
T20	Exp 906 910	that
T21	Exp 934 941	neither
T22	Exp 867 892	this apparent discrepancy
T23	Exp 934 949	neither aspirin
T24	Exp 1155 1160	which
T25	Exp 1079 1095	This observation
T26	Exp 1393 1404	the ability
T27	Exp 1435 1449	the activation
T28	Exp 1453 1477	the transcription factor
T29	Exp 1336 1359	This different behavior
T30	Exp 1672 1690	its metabolite HTB
T31	Exp 1587 1605	the COX-2 activity
T32	Exp 1691 1705	the expression
T33	Exp 1731 1745	the resumption
T34	Exp 1828 1833	which
T35	Exp 1926 1931	which
R7	Coref Anaphora:T11 Antecedent:T36
R8	Coref Anaphora:T12 Antecedent:T37
R9	Coref Anaphora:T16 Antecedent:T38
R10	Coref Anaphora:T30 Antecedent:T39
R11	Coref Anaphora:T34 Antecedent:T40
R12	Coref Anaphora:T35 Antecedent:T41
T1	Protein 14 30	cyclooxygenase-2
T2	Protein 239 255	cyclooxygenase-2
T3	Protein 512 528	cyclooxygenase-2
T4	Protein 530 535	COX-2
T5	Protein 687 692	COX-2
T6	Protein 845 850	COX-2
T7	Protein 1015 1020	COX-2
T8	Protein 1318 1323	COX-2
T9	Protein 1591 1596	COX-2
T10	Protein 1842 1847	COX-2
T36	Exp 78 88	salicylate
T37	Exp 205 210	drugs
T38	Exp 328 368	2-acetoxy-4-trifluoromethyl-benzoic acid
T39	Exp 1637 1646	triflusal
T40	Exp 1815 1824	processes
T41	Exp 1899 1922	pathological situations
